Fate Therapeutics, Inc. (FATE)

Fate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	37.91	41.87	61.33	133.58	167.35	99.81
Short-Term Investments	259.01	273.31	374.89	482.33	315.57	121.61
Cash & Short-Term Investments	296.92	315.18	436.23	615.91	482.92	221.43
Cash Growth	-15.10%	-27.75%	-29.17%	27.54%	118.09%	10.16%
Accounts Receivable	4.13	1.83	38.48	8.68	5.52	-
Other Receivables	1.9	0.9	0.8	1.1	1.5	1
Receivables	6.03	2.73	39.28	9.78	7.02	1
Prepaid Expenses	7.34	13.64	26.57	7.73	4.39	4.66
Total Current Assets	310.29	331.54	502.07	633.41	494.32	227.09
Property, Plant & Equipment	140.83	158.51	176.09	162.25	99.39	34.17
Long-Term Investments	33.61	0.98	4.94	100.66	-	39.44
Long-Term Deferred Charges	-	-	7.2	9.87	13.51	1.34
Other Long-Term Assets	10.24	15.19	15.26	15.26	15.24	0.24
Total Assets	494.97	506.22	705.56	921.46	622.46	302.27
Accounts Payable	6.35	4.72	8.27	8.61	6.28	5.82
Accrued Expenses	23.58	27.51	53.93	42.41	15.56	14.7
Current Portion of Leases	6.89	6.18	5.63	5.58	3.36	1.69
Current Unearned Revenue	0.6	0.69	42.23	21.48	21.14	2.79
Other Current Liabilities	-	-	4	3.2	39.22	2.81
Total Current Liabilities	37.42	39.09	114.05	81.28	85.56	27.81
Long-Term Leases	92.09	97.36	103.71	109.24	93.94	25.24
Long-Term Unearned Revenue	-	-	-	27.12	46.02	3.78
Other Long-Term Liabilities	3.14	1.35	3.86	24.97	12.48	0.7
Total Liabilities	132.64	137.8	221.62	242.62	238.01	57.52
Common Stock	0.11	0.1	0.1	0.1	0.09	0.08
Additional Paid-In Capital	1,707	1,580	1,536	1,449	941.22	628.2
Retained Earnings	-1,346	-1,212	-1,051	-769.08	-556.93	-383.55
Comprehensive Income & Other	0.84	0.02	-1.85	-0.76	0.07	0.02
Total Common Equity	362.32	368.41	483.94	678.84	384.44	244.75
Shareholders' Equity	362.33	368.42	483.94	678.84	384.45	244.76
Total Liabilities & Equity	494.97	506.22	705.56	921.46	622.46	302.27
Total Debt	98.98	103.54	109.34	114.82	97.3	26.93
Net Cash (Debt)	197.95	211.64	326.89	501.09	385.62	194.5
Net Cash Growth	-19.13%	-35.26%	-34.76%	29.95%	98.26%	4.50%
Net Cash Per Share	1.82	2.15	3.38	5.29	4.68	2.85
Filing Date Shares Outstanding	113.89	99.24	98.16	96.43	93.78	75.93
Total Common Shares Outstanding	113.88	98.63	97.29	95.73	87.72	75.73
Working Capital	272.87	292.45	388.02	552.13	408.76	199.28
Book Value Per Share	3.18	3.74	4.97	7.09	4.38	3.23
Tangible Book Value	362.32	368.41	483.94	678.84	384.44	244.75
Tangible Book Value Per Share	3.18	3.74	4.97	7.09	4.38	3.23
Machinery	-	83.29	81.5	53.63	22.25	17.17
Construction In Progress	-	-	-	-	18.19	0.2
Leasehold Improvements	-	59.04	56.78	52.95	2.7	2.47

Source: S&P Capital IQ. Standard template. Financial Sources.